Abstract: The present invention provides a method for producing a transgenic (Tg) non-human animal capable of developing an enhanced humoral immune response against an antigen as compared to a non-transgenic control animal of the same species, comprising introducing into said non-human animal a genetic construct providing for enhanced MHC class I-related neonatal Fc receptor (FcRn) activity. Also provided a Tg non-human animal comprising a genetic construct providing for enhanced FcRn activity, as well as the use of such animal in a non-therapeutical method. Therapeutic genetic constructs and methods are also provided. The present invention further provides methods for producing immunoglobulins.

Abstract: The invention relates to an isolated nucleic acid comprising a sequence encoding a half transporter protein of the ABCG-family for use in gene therapy, to the use of the isolated nucleic acid for selecting somatic mammalian cells against at least one drug transportable by the transporter protein, to vectors, cells, pharmaceutical compositions and kits comprising the nucleic acid and methods for protecting and selecting cells against a cytotoxic drug transportable by said transporter protein and for gene therapy methods.